Preview

Артериальная гипертензия

Расширенный поиск

Обновление Европейских рекомендаций по лечению артериальной гипертензии: анализ Европейского Общества Гипертензии

Полный текст:

Список литературы

1. Mancia G., De Backer G., Dominiczak A. et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // J. Hypertens. - 2007. - Vol. 25. - P. 1105-1187.

2.

3. Havranek E.P., Froshaug D.B., Emserman C.D. et al. Left ventricular hypertrophy and cardiovascular mortality by race and ethnicity // Am. J. Med. - 2008. - Vol. 121. - P. 870-875.

4.

5. Li Z., Dahlof B., Okin P.M.et al. Bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan intervention for endpoint reduction in hypertension study // J. Hypertens. - 2008. - Vol. 26. - P. 1244- 1249.

6.

7. Verdecchia P., Angeli F., Cavallini C. et al. The voltage of R wave in lead aVL improves risk stratifi cation in hypertensive patients without ECG left ventricular hypertrophy // J. Hypertens. - 2009. - Vol. 27. - P. 1697-1704.

8.

9. Milani R.V., Lavie C.J., Mehra M.R. et al. Left ventricular geometry and survival in patients with normal left ventricular ejection fraction // Am.J. Cardiol. - 2006. - Vol. 97. - P. 959-963.

10.

11. Taylor H.A., Penman A.D., Han H. et al. Left ventricular architecture and survival in African-Americans free of coronary heart disease (from the Atherosclerosis Risk In Communities [ARIC] study) // Am. J. Cardiol. - 2007. - Vol. 99. - P. 1413-1420.

12.

13. Tsioufi s C., Vezali E., Tsiachris D. et al. Left ventricular hypertrophy versus chronic kidney disease as predictors of cardiovascular events in hypertension: a Greek 6-year-follow-up study // J. Hypertens. - 2009. - Vol. 27. - P. 744-752.

14.

15. Yasuno S., Ueshima K., Oba K. et al. Clinical signifi cance of left ventricular hypertrophy and changes in left ventricular mass in high-risk hypertensive patients: a subanalysis of the candesartan antihypertensive survival evaluation in Japan trial // J. Hypertens. - 2009. - Vol. 27. - P. 1705-1712.

16.

17. Bombelli M., Facchetti R., Carugo S. et al. Left ventricular hypertrophy increases cardiovascular risk independently of in- and out-of offi ce blood pressure values // J. Hypertens. - 2009. // [Epub ahead of print].

18.

19. Zanchetti A., Hennig M., Hollweck R. et al. Baseline values but not treatment induced changes in carotid intima media thickness predict incident cardiovascular events in treated hypertensives. Findings in the ELSA // Circulation. - 2009. - Vol. 120. - P. 1084-1090.

20.

21. Sehestedt T., Jeppesen J., Hansen T.W. et al. Which markers of subclinical organ damage to measure in individuals with high normal blood pressure? // J. Hypertens. - 2009. - Vol. 27. - P. 1165-1171.

22.

23. Inoue M., Maeda R., Kawakami H. et al. Aortic pulse wave velocity predicts cardiovascular mortality in middle-aged and elderly Japanese men // Circ. J. - 2009. - Vol. 73. - P. 549-553.

24.

25. Jankowski P., Kawecka-Jaszcz K., Czarnecka D. et al. Aortic blood pressure and survival study group. Pulsatile but not steady component of blood pressure predicts cardiovascular events in coronary patients // Hypertension. - 2008. - Vol. 51. - P. 848-855.

26.

27. Wang K.L., Cheng H.M., Chuang S.Y. et al. Central or peripheral systolic or pulse pressure: which best relates to target organs and future mortality? // J. Hypertens. - 2009. - Vol. 27. - P. 461-467.

28.

29. Cuspidi C. Cardio-renal organ damage and cardiovascular outcomes in hypertension // J. Hypertens. - 2009. - Vol. 27. - P. 702-706.

30.

31. Cirillo M., Lanti M.P., Menotti A. et al. Defi nition of kidney dysfunction as a cardiovascular risk factor: use of urinary albumin excretion and estimated glomerular fi ltration rate // Arch. Intern. Med. - 2008. - Vol. 168. - P. 617-624.

32.

33. Ruilope L.M., Zanchetti A., Julius S. et al. VALUE Investigators. Prediction of cardiovascular outcome by estimated glomerular fi ltration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial // J. Hypertens. - 2007. - Vol. 25. - P. 1473-1479.

34.

35. Ninomiya T., Perkovic V., de Galan B.E. et al. ADVANCE Collaborative Group. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes // J. Am. Soc. Nephrol. - 2009. - Vol. 20. - P. 1813-1821.

36.

37. Waeber B., de la Sierra A., Ruilope L.M. Target organ damage: how to detect it and how to treat it? // J. Hypertens. - 2009. - Vol. 27 (Suppl. 3). - P. S13-S18.

38.

39. De Zeeuw D. Albuminuria: a target for treatment of type 2 diabetic nephropathy // Semin. Nephrol. - 2007. - Vol. 27. - P. 172-181.

40.

41. Kearney-Schwartz A., Rossignol P., Bracard S. et al. Vascular structure and function is correlated to cognitive performance and white matter hyperintensities in older hypertensive patients with subjective memory complaints // Stroke. - 2009. - Vol. 40. - P. 1229-1236.

42.

43. Henskens L.H., van Oostenbrugge R.J., Kroon A.A. et al. Detection of silent cerebrovascular disease refi nes risk stratifi cation of hypertensive patients // J. Hypertens. - 2009. - Vol. 27. - P. 846-853.

44.

45. Stewart R., Xue Q.L., Masaki K. et al. Change in blood pressure and incident dementia. A 32-year prospective study // Hypertension. - 2009. - Vol. 54. - P. 233-240.

46.

47. World Health Organization. Life in the 21st century: a vision for all: the World Health Report // Geneva, Switzerland: World Health Organization, 1998.

48.

49. De Ciuceis C., Porteri E., Rizzoni D. et al. Structural alterations of subcutaneous small arteries may predict major cardiovascular events in hypertensive patients // Am. J. Hypertens. - 2007. - Vol. 20. - P. 846-852.

50.

51. Mathiassen O.N., Buus N.H., Sihm I. et al. Small artery structure is an independent predictor of cardiovascular events in essential hypertension //J. Hypertens. - 2007. - Vol. 25. - P. 1021-1026.

52.

53. Harazny J.M., Ritt M., Baleanu D. et al. Increased wall:lumen ratio of retinal arterioles in male patients with a history of a cerebrovascular event // Hypertension. - 2007. - Vol. 50. - P. 623-829.

54.

55. Shimbo D., Grahame-Clarke C., Miyake Y. et al. The association between endothelial dysfunction and cardiovascular outcomes in a population-based multiethnic cohort // Atherosclerosis. - 2007. - Vol. 192. - P. 197-203.

56.

57. Yeboah J., Crouse J.R., Hsu F.-C. et al. // Brachial fl owmediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study // Circulation. - 2007. - Vol. 115. - P. 2390-2397.

58.

59. Muiesan M.L., Salvetti M., Paini A. et al. Prognostic role of fl ow-mediated dilatation of the brachial artery in hypertensive patients //J. Hypertens. - 2008. - Vol. 26. - P. 1612-1618.

60.

61. Rizzoni D., Porteri E., De Ciuceis C. et al. Lack of prognostic role of endothelial dysfunction in subcutaneous small resistance arteries of hypertensive patients // J. Hypertens. - 2006. - Vol. 24. - P. 867-873.

62.

63. Wang T.J., Gona P., Larson M.G. et al. Multiple biomarkers for the prediction of fi rst major cardiovascular events and death // N. Engl. J. Med. - 2006. - Vol. 355. - P. 2631-2639.

64.

65. Koren M.J., Devereux R.B., Casale P.N. et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension // Ann. Intern. Med. - 1991. - Vol. 114. - P. 345-352.

66.

67. Levy D., Garrison R.J., Savage D.D. et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study // N. Engl. J. Med. - 1990. - Vol. 322. - P. 1561-1566.

68.

69. O'Leary D.H., Polak J.F., Kronmal R.A.et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group //N. Engl. J. Med. - 1999. - Vol. 340. - P. 14-22.

70.

71. Laurent S., Cockcroft J., Van Bortel L. et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications // Eur. Heart J. - 2006. - Vol. 27. - P. 2588-2605.

72.

73. Fowkes G.F., and the Ankle Brachial Index Collaboration. Ankle brachial index combined with Framingham Risk Score to predict 36 РЕКОМЕНДАЦИИ Том 16, № 1 / 2010 cardiovascular events and mortality: a meta-analysis // J. Am. Med. Assoc. - 2008. - Vol. 300. - P. 197-200.

74.

75. De Buyzere M., Clement D.L. Management of hypertension in peripheral arterial disease // Progress Cardiovasc. Dis. - 2008. - Vol. 50. - P. 238-263.

76.

77. Ruilope L.M., Salvetti A., Jamerson K. et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) study // J. Am. Soc. Nephrol. - 2001. - Vol. 12. - P. 218-225.

78.

79. De Leeuw P.W., Ruilope L.M., Palmer C.R. et al. Clinical signifi cance of renal function in hypertensive patients at high risk: results from the INSIGHT trial // Arch. Intern. Med. - 2004. - Vol. 164. - P. 2459-2464.

80.

81. Jensen J.S., Feldt-Rasmussen B., Strandgaard S. et al. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease // Hypertension. - 2000. - Vol. 35. - P. 898-903.

82.

83. Culleton B.F., Larson M.G., Wilson P.W. et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insuffi ciency // Kidney Int. - 1999. - Vol. 56. - P. 2214-2219.

84.

85. Hillege H.L., Fidler V., Diercks G.F. et al. Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population // Circulation. - 2002. - Vol. 106. - P. 1777-1782.

86.

87. Conroy R.M., Pyorala K., Fitzgerald A.P. et al. SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project // Eur. Heart J. - 2003. - Vol. 24. - P. 987-1003.

88.

89. Arnlov J., Evans J.C., Meigs J.B. et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study // Circulation. - 2005. - Vol. 112. - P. 969-975.

90.

91. Devereux R.B., Wachtell K., Gerdts E. et al. Prognostic signifi cance of left ventricular mass change during treatment of hypertension // J. Am. Med. Assoc. - 2004. - Vol. 292. - P. 2350-2356.

92.

93. Ibsen H., Olsen M.H., Wachtell K. et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan Intervention For Endpoint reduction in hypertension study // Hypertension. - 2005. - Vol. 45. - P. 198-202.

94.

95. De Zeeuw D., Parving H.H., Henning R.H. Microalbuminuria as an early marker for cardiovascular disease // J. Am. Soc. Nephrol. - 2006. - Vol. 17. - P. 2100-2105.

96.

97. Gerdts E., Wachtell K., Omvik P. et al. Left atrial size and risk of major cardiovascular events during antihypertensive treatment: Losartan Intervention For Endpoint reduction in hypertension trial // Hypertension. - 2007. - Vol. 49. - P. 311-316.

98.

99. Gerdts E., Cramariuc D., de Simone G. et al. Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study) // Eur. J. Echocardiogr. - 2008. - Vol. 9. - P. 809-815.

100.

101. Okin P.M., Devereux R.B., Jern S. et al. LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy duringantihypertensive treatment and the prediction of major cardiovascular events // J. Am. Med. Assoc. - 2004. - Vol. 292. - P. 2343-2349.

102.

103. Muiesan M.L., Salvetti M., Paini A. et al. Inappropriate left ventricular mass changes during treatment adversely affects cardiovascular prognosis in hypertensive patients // Hypertension. - 2007. - Vol. 49. - P. 1077-1083.

104.

105. Mann J.F., Schmieder R.E., McQueen M. et al. ONTARGET Investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, doubleblind, controlled trial // Lancet. - 2008. - Vol. 372. - P. 547-553.

106.

107. Mancia G., Bombelli M., Corrao G. et al. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis // Hypertension. - 2007. - Vol. 49. - P. 40-47.

108.

109. Mancia G., Bombelli M., Facchetti R. et al. Long-term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population // J. Hypertens. - 2008. - Vol. 26. - P. 1602-1611.

110.

111. Norton G.R., Maseko M., Libhaber E. et al. Is prehypertension an independent predictor of target organ changes in young-to-middle-aged persons of African descent? // J. Hypertens. - 2008. - Vol. 26. - P. 2279-2987.

112.

113. Isles C.G., Walker L.M., Beevers G.D. et al. Mortality in patients of the Glasgow Blood Pressure Clinic // J. Hypertens. - 1986. - Vol. 4. - P. 141-156.

114.

115. Lindholm L., Ejlertsson G., Schersten B. High risk of cerebrocardiovascular morbidity in well treated male hypertensives. A retrospective study of 40-59-year-old hypertensives in a Swedish primary care district // Acta Med. Scand. - 1984. - Vol. 216. - P. 251-259.

116.

117. Thurmer H.L., Lund-Larsen P.G., Tverdal A. Is blood pressure treatment as effective in a population setting as in controlled trials? Results from a prospective study // J. Hypertens. - 1994. - Vol. 12. - P. 481-490.

118.

119. Benetos A., Thomas F., Bean K.E., Guize L. Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population // J. Hypertens. - 2003. - Vol. 21. - P. 1635-1640.

120.

121. Almgren T., Persson B., Wilhelmsen L. et al. Stroke and coronary heart disease in treated hypertension: a prospective cohort study over three decades // J. Intern. Med. - 2005. - Vol. 257. - P. 496-502.

122.

123. Asayama K., Ohkubo T., Yoshida S. et al. Japan Arteriosclerosis Longitudinal Study (JALS) group. Stroke risk and antihypertensive drug treatment in the general population: the Japan Arteriosclerosis Longitudinal Study // J. Hypertens. - 2009. - Vol. 27. - P. 357-364.

124.

125. Zanchetti A. Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced? // J. Hypertens. - 2009. - Vol. 27. - P. 1509-1520.

126.

127. Ibsen H. Antihypertensive treatment and risk of cardiovascular complications: is the cure worse than the disease? // J. Hypertens. - 2009. - Vol. 27. - P. 221-223.

128.

129. Guidelines Sub-Committee. 1999 World Health Organization/ International Society of Hypertension Guidelines for the management of hypertension // J. Hypertens. - 1999. - Vol. 17. - P. 151-183.

130.

131. Chobanian A.V., Bakris G.L., Black H.R. et al. Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure // Hypertension. - 2003. - Vol. 42. - P. 1206-1252.

132.

133. Sanchez R.A., Ayala M., Baglivo H. et al. Latin America Expert Group. Latin American guidelines on hypertension // J. Hypertens. - 2009. - Vol. 27. - P. 905-922.

134.

135. Ogihara T., Kikuchi K., Matsuoka H. et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009) // Hypertens. Res. - 2009. - Vol. 32. - P. 3-107.

136.

137. Graham I., Atar D., Borch-Johnsen K. et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts) // Eur. J. Cardiovasc. Prev. Rehabil. - 2007. - Vol. 14 (Suppl. 2). - P. E1-E40.

138.

139. Zanchetti A., Grassi G., Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal // J. Hypertens. - 2009. - Vol. 27. - P. 923-934.

140.

141. Medical Research Council trial of treatment of mild hypertension: principal results. MRC Working Party // Br. Med. J. - 1985. - Vol. 291. - P. 97-104.

142.

143. Management Committee. The Australian therapeutic trial in mild hypertension // Lancet. - 1980. - Vol. 1. - P. 1261-1267.

144.

145. Hypertension detection and follow-up program cooperative group: The effect of treatment on mortality in 'mild' hypertension: results of the Hypertension detection and follow-up program // N. Engl. J. Med. - 1982. - Vol. 307. - P. 976-980.

146.

147. Liu L., Zhang Y., Liu G. et al. FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebocontrolled trial in Chinese hypertensive patients // J. Hypertens. - 2005. - Vol. 23. - P. 2157-2172.

148.

149. Amery A., Birkenhager W., Brixko P. et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial // Lancet. - 1985. - Vol. 1. - P. 1349-1354. 37 Том 16, № 1 / 2010

150.

151. Coope J., Warrender T.S. Randomised trial of treatment of hypertension in elderly patients in primary care // Br. Med. J. (Clin. Res. Ed.). - 1986. - Vol. 293. - P. 1145-1151.

152.

153. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP) // J. Am. Med. Assoc. - 1991. - Vol. 265. - P. 3255-3264.

154.

155. Dahlof B., Lindholm L.H., Hansson L. et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOPHypertension) // Lancet. - 1991. - Vol. 338. - P. 1281-1285.

156.

157. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results // Br. Med. J. - 1992. - Vol. 304. - P. 405-412.

158.

159. Staessen J.A., Fagard R., Thijs L. et al. for The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised doubleblind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst- Eur) Trial Investigators // Lancet. - 1997. - Vol. 350. - P. 757-764.

160.

161. Liu L., Wang J.G., Gong L. et al. for the Systolic Hypertension in China (Syst-China) Collaborative Group. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension //J. Hypertens. - 1998. - Vol. 16. - P. 1823-1829.

162.

163. Lithell H., Hansson L., Skoog I. et al. SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE). Principal results of a randomised double-blind intervention trial // J. Hypertens. - 2003. - Vol. 21. - P. 875-886.

164.

165. Beckett N.S., Peters R., Fletcher A.E. et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older // N. Engl. J. Med. - 2008. - Vol. 358. - P. 1887-1898.

166.

167. JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS) // Hypertens. Res. - 2008. - Vol. 31. - P. 2115-2127.

168.

169. Schrier R.W., Estacio R.O., Esler A., Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes // Kidney Int. - 2002. - Vol. 61. - P. 1086-1097.

170.

171. Heart Outcomes Prevention Evaluation (HOPE) Study investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy // Lancet. - 2000. - Vol. 355. - P. 253-259.

172.

173. ADVANCE Collaborative Group. Effects of a fi xed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial // Lancet. - 2007. - Vol. 370. - P. 829-840.

174.

175. PROGRESS Collaborative Study Group. Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack // Lancet. - 2001. - Vol. 358. - P. 1033-1041.

176.

177. Arima H., Chalmers J., Woodward M. et al. for the PROGRESS Collaborative Group. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial // J. Hypertens. - 2006. - Vol. 24. - P. 1201-1208.

178.

179. Yusuf S., Diener H.C., Sacco R.L. et al. PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events // N. Engl.J. Med. - 2008. - Vol. 359. - P. 1225-1237.

180.

181. Zanchetti A., Mancia G., Black H.R. et al. Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension // J. Hypertens. - 2009. - Vol. 27. - P. 673-679.

182.

183. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients // N. Engl. J. Med. - 2002. - Vol. 342. - P. 145-153.

184.

185. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Effi cacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) // Lancet. - 2003. - Vol. 362. - P. 782-788.

186.

187. Nissen S.E., Tuzcu E.M., Libby P. et al. CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study - a randomized controlled trial // J. Am. Med. Assoc. - 2004. - Vol. 292. - P. 2217-2225.

188.

189. Poole-Wilson P.A., Lubsen J., Kirwan B.A. et al. Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): a randomised controlled trial // Lancet. - 2004. - Vol. 364. - P. 849-857.

190.

191. The PEACE trial investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease // N. Engl. J. Med. - 2004. - Vol. 351. - P. 2058-2068.

192.

193. Helgeland A. Treatment of mild hypertension: a fi ve year controlled drug trial. The Oslo study // Am. J. Med. - 1980. - Vol. 69. - P. 725-732.

194.

195. Hansson L., Zanchetti A., Carruthers S.G. et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group // Lancet. - 1998. - Vol. 351. - P. 1755-1762.

196.

197. Curb J.D., Pressel S.L., Cutler J.A. et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic hypertension in the Elderly Program Cooperative Research Group // J. Am. Med. Assoc. - 1996. - Vol. 276. - P. 1886-1892.

198.

199. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 // Br. Med. J. - 1998. - Vol. 317. - P. 703-713.

200.

201. Tuomilehto J., Rastenyte D., Birkenhager W.H. et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic hypertension in Europe Trial Investigators // N. Engl.J. Med. - 1999. - Vol. 340. - P. 677-684.

202.

203. Estacio R.O., Jeffers B.W., Gifford N., Schrier R.W. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes // Diabetes Care. - 2000. - Vol. 23 (Suppl. 2). - P. B54-B64.

204.

205. Lewis E.J., Hunsicker L.G., Clarke W.R. et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes // N. Engl. J. Med. - 2001. - Vol. 345. - P. 851-860.

206.

207. Brenner B.M., Cooper M.E., de Zeeuw D. et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy // N. Engl. J. Med. - 2001. - Vol. 345. - P. 861-869.

208.

209. Berthet K., Neal B.C., Chalmers J.P. et al. Perindopril protection against recurrent stroke Study Collaborative Group. Reductions in the risks of recurrent stroke in patients with and without diabetes: the PROGRESS Trial // Blood Press. - 2004. - Vol. 13. - P. 7-13.

210.

211. Pitt B., Byington R.P., Furberg C.D. et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators // Circulation. - 2000. - Vol. 102. - P. 1503-1510.

212.

213. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial // Lancet. - 2008. - Vol. 372. - P. 1174-1183.

214.

215. Weber M.A., Julius S., Kjeldsen S.E. et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial // Lancet. - 2004. - Vol. 363. - P. 2049- 2051.

216.

217. Mancia G., Messerli F.H., Weber M.A. et al. Association between the proportion of time under blood pressure (BP) control and cardiovascular (CV) morbidity and mortality in the VALUE trial // J. Hypertens. - 2009. - Vol. 27 (Suppl. 4). - P. S327.

218.

219. Pepine C.J., Handberg E.M., Cooper-DeHoff R.M. et al. INVEST Investigators. A calcium antagonist vs a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial //J. Am. Med. Assoc. - 2003. - Vol. 290. - P. 2805-2816.

220.

221. Mancia G., Messerli F., Bakris G. et al. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SRTrandolapril Study // Hypertension. - 2007. - Vol. 50. - P. 299-305.

222.

223. Messerli F.H., Mancia G., Conti C.R. et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? // Ann. Intern. Med. - 2006. - Vol. 144. - P. 884-893.

224.

225. Bakris G.L., Gaxiola E., Messerli F.H. et al. INVEST Investigators. Clinical outcomes in the diabetes cohort of the INternational VErapamil SRTrandolapril study // Hypertension. - 2004. - Vol. 44. - P. 637-642. Том 16, № 1 / 2010

226.

227. Sleight P., Redon J., Verdecchia P. et al. ONTARGET investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study // J. Hypertens. - 2009. - Vol. 27. - P. 1360-1369.

228.

229. Redon J., Sleight P., Mancia G. et al. Safety and effi cacy of aggressive blood pressure lowering among patients with diabetes: subgroup analyses from the ONTARGET trial // J. Hypertens. - 2009. - Vol. 27 (Suppl. 4). - P. S16.

230.

231. Berl T., Hunsicker L.G., Lewis J.B. et al. Collaborative Study Group. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial // J. Am. Soc. Nephrol. - 2005. - Vol. 16. - P. 2170-2179.

232.

233. Pohl M.A., Blumenthal S., Cordonnier D.J. et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the Irbesartan Diabetic Nephropathy Trial: clinical implications and limitations // J. Am. Soc. Nephrol. - 2005. - Vol. 16. - P. 3027-3037.

234.

235. Okin P.M., Devereux R.B., Jern S. et al. Losartan Intervention For Endpoint reduction in hypertension Study Investigations. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention For Endpoint reduction in hypertension (LIFE) Study // Circulation. - 2003. - Vol. 108. - P. 684-690.

236.

237. Verdecchia P., Staessen J.A., Angeli F. et al. Cardio-Sis investigators. Usual versus tight control of systolic blood pressure in nondiabetic patients with hypertension (Cardio-Sis): an open-label randomised trial // Lancet. - 2009. - Vol. 374. - P. 525-533.

238.

239. The ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data // Ann. Int. Med. - 2001. - Vol. 134. - P. 370-379.

240.

241. Parving H.H., Hommel E., Jensen B.R., Hansen H.P. Long-term benefi cial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients // Kidney Int. - 2001. - Vol. 60. - P. 228-234.

242.

243. de Galan B.E., Perkovic V., Ninomiya T. et al. ADVANCE Collaborative Group. Lowering blood pressure reduces renal events in type 2 diabetes // J. Am. Soc. Nephrol. - 2009. - Vol. 20. - P. 883-892.

244.

245. Bangalore S., Messerli F.H., Wun C. et al. Treating to new targets Steering Committee and Investigators. J-Curve revisited: an analysis of the Treating to New Targets (TNT) Trial // J. Am. Coll. Cardiol. - 2009. - Vol. 53. - P. A217.

246.

247. Lewington S., Clarke R., Qizilbash N. et al. Prospective Studies Collaboration. Age-specifi c relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies // Lancet. - 2002. - Vol. 360. - P. 1903-1913.

248.

249. Polese A., De Cesare N., Montorsi P. et al. Upward shift of the lower range of coronary fl ow autoregulation in hypertensive patients with hypertrophy of the left ventricle // Circulation. - 1991. - Vol. 83. - P. 845-853.

250.

251. Boutitie F., Gueyffi er F., Pocock S. et al. J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individual-patient data // Ann. Intern. Med. - 2002. - Vol. 136. - P. 438-448.

252.

253. Buse J.B., Bigger J.T., Byington R.P. et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods //Am. J. Cardiol. - 2007. - Vol. 99, № 12A. - P. 21i-33i.

254.

255. Julius S., Nesbitt S.D., Egan B.M. et al. Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker // N. Engl. J. Med. - 2006. - Vol. 354. - P. 1685-1697.

256.

257. Luders S., Schrader J., Berger J. et al. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure. - P. a prospective, randomized, controlled prevention trial of the German Hypertension League // J. Hypertens. - 2008. - Vol. 26. - P. 1487-1496.

258.

259. Laurent S., Briet M., Boutouyrie P. Large/small artery cross talk and recent morbidity-mortality trials in hypertension // Hypertension. - 2009. - Vol. 54. - P. 388-392.

260.

261. Staessen J.A., Thijis L., Fagard R. et al. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic hypertension in Europe Trial // J. Hypertens. - 2004. - Vol. 22. - P. 847-857.

262.

263. Kostis J.B., Wilson A.C., Freudenberger R.S. et al. SHEP Collaborative Research Group. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes // Am. J. Cardiol. - 2005. - Vol. 95. - P. 29-35.

264.

265. Gaede P., Lund-Andersen H., Parving H.H., Pederson O. Effect of a multifactorial intervention on mortality in type 2 diabetes // N. Engl.J. Med. - 2008. - Vol. 358. - P. 580-591.

266.

267. Holman R.R., Paul S.K., Bethel M.A. 10-years follow-up of intensive glucose control in type 2 diabetes // N. Engl. J. Med. - 2008. - Vol. 359. - P. 1577-1589.

268.

269. Guidelines Committee. 2003 European Society of Hypertension- European Society of Cardiology guidelines for the management of arterial hypertension // J. Hypertens. - 2003. - Vol. 21. - P. 1011-1053.

270.

271. Jick H., Slone D., Shapiro S. et al. Boston Collaborative Drug Surveillance Program. Reserpine and breast cancer // Lancet. - 1974. - Vol. II. - P. 669-677.

272.

273. Psaty B.M., Heckbert S.R., Koepsell T.D. et al. The risk of myocardial infarction associated with antihypertensive drug therapies // J.Am. Med. Assoc. - 1995. - Vol. 274. - P. 620-625.

274.

275. Pahor M., Guralnik J.M., Corti M.C. et al. Long-term survival and uses of antihypertensive medications in older persons // J. Am. Geriatr. Soc. - 1995. - Vol. 49. - P. 1191-1197.

276.

277. Lindholm L.H., Carlberg B., Samuelsson O. Should beta blockers remain fi rst choice in the treatment of primary hypertension? A metaanalysis // Lancet. - 2005. - Vol. 366. - P. 1545-1553.

278.

279. Hypertension: management of hypertension in adults in primary care // NICE/BHS. - Vol. 2006. - [Электронный ресурс]. - Режим доступа: www.nice.org.uk/CG034.

280.

281. Opie L.H. Beta-blockade should not be among several choices for initial therapy of hypertension // J. Hypertens. - 2008. - Vol. 26. - P. 161-163.

282.

283. Messerli F.H., Bangalore S., Julius S. Risk/benefi t assessment of beta-blockers and diuretics precludes their use for fi rst-line therapy in hypertension // Circulation. - 2008. - Vol. 117. - P. 2706-2715.

284.

285. Mancia G. Prevention of risk factors: beta-blockade and hypertension // Eur. Heart J. Suppl. - 2009. - Vol. 11. - P. A3-A8.

286.

287. Bangalore S., Sawhney S., Messerli F.H. Relation of beta-blockerinduced heart rate lowering and cardioprotection in hypertension // J. Am. Coll. Cardiol. - 2008. - Vol. 52. - P. 1482-1489.

288.

289. Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefi ts in postmyocardial infarction: a meta-regression of randomized clinical trials // Eur. Heart J. - 2007. - Vol. 28. - P. 3012-3019.

290.

291. Houghton T., Freemantle N., Cleland J.G. Are beta-blockers effective in patients who develop heart failure soon after myocardial infarction? A meta-regression analysis of randomised trials // Eur. J. Heart Fail. - 2000. - Vol. 2. - P. 333-340.

292.

293. Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies // Br. Med. J. - 2009. - Vol. 338. - P. 1665-1683.

294.

295. Holman R.R., Paul S.K., Bethel M.A. et al. Long-term followup after tight control of blood pressure in type 2 diabetes // N. Engl.J. Med. - 2008. - Vol. 359. - P. 1565-1576.

296.

297. Blackburn D.F., Lamb D.A., Eurich D.T. et al. Atenolol as initial antihypertensive therapy: an observational study comparing fi rst-line agents // J. Hypertens. - 2007. - Vol. 25. - P. 1499-1505.

298.

299. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials // Lancet. - 2003. - Vol. 362. - P. 1527-1535.

300.

301. Mancia G., Zanchetti A. Choice of antihypertensive drugs in the European Society of Hypertension-European Society of Cardiology guidelines: specifi c indications rather than ranking for general usage //J. Hypertens. - 2008. - Vol. 26. - P. 164-168.

302.

303. Wald D.S., Law M., Morris J.K. et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials // Am. J. Med. - 2009. - Vol. 122. - P. 290-300.

304.

305. Williams B., Lacy P.S., Thom S.M. et al. CAFE Investigators: Anglo-Scandinavian Cardiac Outcomes Trial Investigators: CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study // Circulation. - 2006. - Vol. 113. - P. 1213-1225.

306.

307. Dart A.M., Cameron J.D., Gatzka C.D. et al. Similar effects of treatment on central and brachial blood pressures in older hypertensive Том 16, № 1 / 2010 subjects in the Second Australian National Blood Pressure Trial // Hypertension. - 2007. - Vol. 49. - P. 1242-1247.

308.

309. Mitchell G.F., Conlin P.R., Dunlap M.E. et al. Aortic diameter, wall stiffness, and wave refl ection in systolic hypertension // Hypertension. - 2008. - Vol. 51. - P. 105-111.

310.

311. Elliott W.J., Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis // Lancet. - 2007. - Vol. 369. - P. 201-207.

312.

313. Mancia G., Grassi G., Zanchetti A. New-onset diabetes and antihypertensive drugs // J. Hypertens. - 2006. - Vol. 24. - P. 3-10.

314.

315. Bangalore S., Parkar S., Grossman E., Messerli F.H. A metaanalysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus // Am. J. Cardiol. - 2007. - Vol. 100. - P. 1254-1262.

316.

317. Zanchetti A., Hennig M., Baurecht H. et al. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness // J. Hypertens. - 2007. - Vol. 25. - P. 2463-2470.

318.

319. Cutler J.A., Davis B.R. Thiazide-type diuretics and betaadrenergic blockers as first-line drug treatments for hypertension // Circulation. - 2008. - Vol. 117. - P. 2691-2704.

320.

321. Barr E.L., Zimmet P.Z., Welborn T.A. et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab) // Circulation. - 2007. - Vol. 116. - P. 151-157.

322.

323. Mozaffarian D., Marfi si R., Levantesi G. et al. Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors // Lancet. - 2007. - Vol. 370. - P. 667-675.

324.

325. Alderman M.H., Cohen H., Madhavan S. Diabetes and cardiovascular events in hypertensive patients // Hypertension. - 1999. - Vol. 33. - P. 1130-1134.

326.

327. Klingbeil A.U., Schneider M., Martus P. et al. A metaanalysis of the effects of treatment on left ventricular mass in essential hypertension //Am. J. Med. - 2003. - Vol. 115. - P. 41-46.

328.

329. Zanchetti A., Bond M.G., Hennig M. et al. European Lacidipine Study on Atherosclerosis investigators. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA) - a randomized, double-blind, long-term trial // Circulation. - 2002. - Vol. 106. - P. 2422-2427.

330.

331. Schiffrin E.L., Deng L.Y. Comparison of effects of angiotensin I-converting enzyme inhibition and beta-blockade for 2 years on function of small arteries from hypertensive patients // Hypertension. - 1995. - Vol. 25, № 4, Pt. 2. - P. 699-703.

332.

333. Schiffrin E.L., Pu Q., Park J.B. Effect of amlodipine compared to atenolol on small arteries of previously untreated essential hypertensive patients // Am. J. Hypertens. - 2002. - Vol. 15. - P. 105-110.

334.

335. Smith R.D., Yokoyama H., Averill D.B. et al. // Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptors // J. Am. Soc. Hypertens. - 2008. - Vol. 2. - P. 165-172.

336.

337. Boutouyrie P., Bussy C., Hayoz D. et al. Local pulse pressure and regression of arterial wall hypertrophy during long term antihypertensive treatment // Circulation. - 2000. - Vol. 101. - P. 2601-2606.

338.

339. Zanchetti A. Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients // Blood Press. - 2004. - Vol. 13 (Suppl. 1). - P. 18-33.

340.

341. Dhakam Z., Yasmin, McEniery C.M. et al. A comparison of atenolol and nebivolol in isolated systolic hypertension // J. Hypertens. - 2008. - Vol. 26. - P. 351-356.

342.

343. Bakris G.L., Fonseca V., Katholi R.E. et al. GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial // J. Am. Med. Assoc. - 2004. - Vol. 292. - P. 2227-2236.

344.

345. Celik T., Iyisoy A., Kursaklioglu H. et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients //J. Hypertens. - 2006. - Vol. 24. - P. 591-596.

346.

347. Kaiser T., Heise T., Nosek L. et al. Infl uence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients // J. Hypertens. - 2006. - Vol. 24. - P. 1397-1403.

348.

349. Dickstein K., Cohen-Solal A., Filippatos G. et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) // Eur. J. Heart Fail. - 2008. - Vol. 10. - P. 933-989.

350.

351. Torp-Pedersen C., Metra M., Charlesworth A. et al. COMET investigators. Effects of metoprolol and carvedilol on preexisting and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET) // Heart. - 2007. - Vol. 93. - P. 968-973.

352.

353. Agabiti Rosei E.,Rizzoni D. Metabolic profi le of nebivolol, a beta-adrenoceptor antagonist with unique characteristics // Drugs. - 2007. - Vol. 67. - P. 1097-1107.

354.

355. Galderisi M., D'Enrico A., Sidiropulos M. et al. Nebivolol induces parallel improvement of left ventricular fi lling pressure and coronary fl ow reserve in uncomplicated arterial hypertension // J. Hypertens. - 2009. - Vol. 27. - P. 2106-2113.

356.

357. Simon A., Gariepy J., Moyse D., Levenson J. Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes // Circulation. - 2001. - Vol. 103. - P. 2949-2954.

358.

359. Zanchetti A., Crepaldi G., Bond M.G. et al. on behalf of PHYLLIS Investigators // Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS: a randomized double-blind trial // Stroke. - 2004. - Vol. 35. - P. 2807-2812.

360.

361. Corrao G., Zambon A., Parodi A. et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy // J. Hypertens. - 2008. - Vol. 26. - P. 819-824.

362.

363. Burke T.A., Sturkenboom M.C., Lu S.E. et al. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice // J. Hypertens. - 2006. - Vol. 24. - P. 1193-1200.

364.

365. Wright G.M., Musini V.M. First-line drugs for hypertension // Cochrane Library. - 2009. - Vol. CD001841. - P. e1-e59.

366.

367. Jamerson K., Weber M.A., Bakris G.L. et al. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients // N. Engl. J. Med. - 2008. - Vol. 359. - P. 2417-2428.

368.

369. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials // Arch. Intern. Med. - 2005. - Vol. 165. - P. 1410-1419.

370.

371. Verdecchia P., Reboldi G., Angeli F. et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention // Hypertension. - 2005. - Vol. 46. - P. 386-392.

372.

373. Boutitie F., Oprisiu R., Achard J.M. et al. Does a change in angiotensin II formation caused by antihypertensive drugs affect the risk of stroke? A meta-analysis of trials according to treatment with potentially different effects on angiotensin II // J. Hypertens. - 2007. - Vol. 25. - P. 1543-1553.

374.

375. Verma S., Strauss M. Angiotensin receptor blockers and myocardial infarction // Br. Med. J. - 2004. - Vol. 329. - P. 1248-1249.

376.

377. Strauss M.H., Hall A.S. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox // Circulation. - 2006. - P. 114. - P. 838-854.

378.

379. ONTARGET Investigators, Yusuf S., Teo K.K., Pogue J. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events //N. Engl. J. Med. - 2008. - Vol. 358. - P. 1547-1559.

380.

381. Reboldi G., Angeli F., Cavallini C. et al. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis //J. Hypertens. - 2008. - Vol. 26. - P. 1282-1289.

382.

383. Volpe M., Tocci G., Sciarretta S. et al. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials // J. Hypertens. - 2009. - Vol. 27. - P. 941-946.

384.

385. Schupp M., Janke J., Clasen R. et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptorgamma activity // Circulation. - 2004. - Vol. 109. - P. 2054-2057.

386.

387. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive Том 16, № 1 / 2010 patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT) // J. Am. Med. Assoc. - 2002. - Vol. 288. - P. 2981-2997.

388.

389. Costanzo P., Perrone-Filardi P., Petretta M. Et al. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients //J. Hypertens. - 2009. - Vol. 27. - P. 1136-1151.

390.

391. Dahlof B., Sever P.S., Poulter N.R. et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial // Lancet. - 2005. - Vol. 366. - P. 895-906.

392.

393. Lubsen J., Wagener G., Kirwan B.A. et al. ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial // J. Hypertens. - 2005. - Vol. 23. - P. 641-648.

394.

395. Fagard R.H. Benefi ts and safety of long-acting calcium antagonists in coronary artery disease: the ACTION Trial // J. Hypertens. - 2005. - Vol. 23. - P. 489-491.

396.

397. Sutton G.C., Erik Otterstad J., Kirwan B.A. et al. ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators. The development of heart failure in patients with stable angina pectoris // Eur. J. Heart Fail. - 2007. - Vol. 9. - P. 234-242.

398.

399. Stanton A. Therapeutic potential of renin inhibitors in the management of cardiovascular disorders // Am. J. Cardiovasc. Drugs. - 2003. - Vol. 3. - P. 389-394.

400.

401. Azizi M., Webb R., Nussberger J., Hollenberg N.K. Renin inhibition with aliskiren: where are we now, and where are we going? //J. Hypertens. - 2006. - Vol. 24. - P. 243-256.

402.

403. O'Brien E., Barton J., Nussberger J. et al. Aliskiren reduces blood pressure and suppresses plasma rennin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker // Hypertension. - 2007. - Vol. 49. - P. 276-284.

404.

405. Villamil A., Chrysant S.G., Calhoun D. et al. Renin inhibition with aliskiren provides additive antihypertensive effi cacy when used in combination with hydrochlorothiazide // J. Hypertens. - 2007. - Vol. 25. - P. 217-226.

406.

407. Littlejohn T.W. 3rd, Trenkwalder P., Hollanders G. et al. Longterm safety, tolerability and effi cacy of combination therapy with aliskiren and amlodipine in patients with hypertension // Curr. Med. Res. Opin. - 2009. - Vol. 25. - P. 951-959.

408.

409. Parving H.H., Persson F., Lewis J.B. et al. AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy // N. Engl. J. Med. - 2008. - Vol. 358. - P. 2433-2446.

410.

411. Solomon S.D., Appelbaum E., Manning W.J. et al. Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy // Circulation. - 2009. - Vol. 119. - P. 530-537.

412.

413. Seed A., Gardner R., McMurray J. et al. Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure //Eur. J. Heart Fail. - 2007. - Vol. 9. - P. 1120-1127.

414.

415. Gardner R.S., Ozalp F., Murday A.J. et al. N-terminal probrain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure // Eur. Heart J. - 2003. - Vol. 24. - P. 1735-1743.

416.

417. Weber M.A., Black H., Bakris G. et al. A selective endothelinreceptor antagonist to reduce blood pressure in patients with treatmentresistant hypertension: a randomized double-blind placebo-controlled trial // Lancet. - 2009. - Vol. 374. - P. 1423-1431.

418.

419. Sarafi dis P.A., Bakris G.L. Resistant hypertension: an overview of evaluation and treatment // J. Am. Coll. Cardiol. - 2008. - Vol. 52. - P. 1749-1757.

420.

421. Report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure. A cooperative study // J. Am. Med. Assoc. - 1977. - Vol. 237. - P. 255-261.

422.

423. Arterial hypertension. Report of a WHO expert committee // World Health Organ. Tech. Rep. Ser. - 1978. - Vol. 628. - P. 7-56.

424.

425. Amar J., Vaur L., Perret M. et al. PRATIK study investigators. Hypertension in high-risk patients: beware of the under use of effective combination therapy (results of the PRATIK study) // J. Hypertens. - 2002. - Vol. 20. - P. 779-784.

426.

427. Kearney P.M., Whelton M., Reynolds K. et al. Global burden of hypertension: analysis of worldwide data // Lancet. - 2005. - Vol. 365. - P. 217-223.

428.

429. Nicotra F., Wettermark B., Sturkenboom M.C. et al. Management of antihypertensive drugs in three European countries // J. Hypertens. - 2009. - Vol. 27. - P. 1917-1922.

430.

431. Ambrosioni E., Leonetti G., Pessina A.C. et al. Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. Scientifi c Committee of the Italian Pharmacoepidemiological Survey on Antihypertensive Therapy //J. Hypertens. - 2000. - Vol. 18. - P. 1691-1699.

432.

433. Bakris G., Molitch M., Hewkin A. et al. STAR Investigators. Differences in glucose tolerance between fi xed-dose antihypertensive drug combinations in people with metabolic syndrome // Diabetes Care. - 2006. - Vol. 29. - P. 2592-2597.

434.

435. Dahlof B., Devereux R.B., Kjeldsen S.E. et al. LIFE Study Group. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol // Lancet. - 2002. - Vol. 359. - P. 995-1003.

436.

437. Lithell H., Hansson L., Skoog I. et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): Outcomes in patients not receiving add-on therapy after randomization // J. Hypertens. - 2004. - Vol. 22. - P. 1605-1612.

438.

439. Kaneshiro Y., Ichihara A., Sakoda M. et al. Add-on benefi ts of amlodipine and thiazide in nondiabetic chronic kidney disease stage 1/2 patients treated with valsartan // Kidney Blood Press. Res. - 2009. - Vol. 32. - P. 51-58.

440.

441. Ichihara A., Kaneshiro Y., Takemitsu T., Sakoda M. Effects of amlodipine and valsartan on vascular damage and ambulatory blood pressure in untreated hypertensive patients // J. Hum. Hypertens. - 2006. - Vol. 20. - P. 787-794.

442.

443. Sanford M., Keam S.J. Olmesartan medoxomil/amlodipine // Drugs. - 2009. - Vol. 69. - P. 717-729.

444.

445. Flack J.M., Hilkert R. Single-pill combination of amlodipine and valsartan in the management of hypertension // Expert Opin. Pharmacother. - 2009. - Vol. 10. - P. 1979-1994.

446.

447. Julius S., Kjeldsen S.E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial // Lancet. - 2004. - Vol. 363. - P. 2022-2031.

448.

449. Ferrari P., Marti H.P., Pfi ster M., Frey F.J. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade //J. Hypertens. - 2002. - Vol. 20. - P. 125-130.

450.

451. Kunz R., Friedrich C., Wolbers M., Mann J.F. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the rennin angiotensin system on proteinuria in renal disease // Ann. Intern. Med. - 2008. - P. 148. - P. 30-48.

452.

453. Eijkelkamp W.B., Zhang Z., Remuzzi G. et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial // J. Am. Soc. Nephrol. - 2007. - Vol. 18. - P. 1540-1546.

454.

455. Nakao N., Yoshimura A., Morita H. et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in nondiabetic renal disease (COOPERATE): a randomised controlled trial // Lancet. - 2003. - Vol. 361. - P. 117-124.

456.

457. Vogt L., Laverman G.D., de Zeeuw D., Navis G. The COOPERATE trial // Lancet. - 2003. - Vol. 361. - P. 1055-1056.

458.

459. Kunz R., Wolbers M., Glass T., Mann J.F. The COOPERATE trial: a letter of concern // Lancet. - 2008. - Vol. 371. - P. 1575-1576.

460.

461. Pfeffer M.A., McMurray J.J., Velazquez E.J. et al. Valsartan in acute myocardial infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both // N. Engl. J. Med. - 2003. - Vol. 349. - P. 1893-1896.

462.

463. Cohn J.N., Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure // N. Engl. J. Med. - 2001. - Vol. 345. - P. 1667-1675.

464.

465. McMurray J.J., Ostergren J., Swedberg K. et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensinconverting-enzyme inhibitors: the CHARM-Added trial // Lancet. - 2003. - Vol. 362. - P. 767-771. 16, № 1 / 2010

466.

467. Bangalore S., Kamalakkannan G., Parkar S., Messerli F.H. Fixeddose combinations improve medication compliance: a meta-analysis // Am.J. Med. - 2007. - Vol. 120. - P. 713-719.

468.

469. Gueyffi er F., Bulpitt C., Boissel J.P. et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA Group // Lancet. - 1999. - Vol. 353. - P. 793-796.

470.

471. Bulpitt C.J., Beckett N.S., Cooke J. et al. Results of the pilot study for the Hypertension in the Very Elderly Trial // J. Hypertens. - 2003. - Vol. 21. - P. 2409-2417.

472.

473. Brown C.M., Hecht M.J., Weih A. et al. Effects of age on the cardiac and vascular limbs of the arterial barorefl ex // Eur. J. Clin. Invest. - 2003. - Vol. 33. - P. 10-16.

474.

475. Blood pressure lowering treatment Trialists' Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials //Br. Med J. - 2008. - Vol. 336. - P. 1121-1123.

476.

477. Mancia G., Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials // J. Hypertens. - 2002. - Vol. 20. - P. 1461-1464.

478.

479. Atkins R.C., Briganti E.M., Lewis J.B. et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy // Am. J. Kidney Dis. - 2005. - Vol. 45. - P. 281-287.

480.

481. Viberti G., Wheeldon N.M. MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressureindependent effect // Circulation. - 2002. - Vol. 106. - P. 672-678.

482.

483. Estacio R.O., Coll J.R., Tran Z.V., Schrier R.W. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes // Am. J. Hypertens. - 2006. - Vol. 19. - P. 1241-1248.

484.

485. Adler A.I., Stratton I.M., Neil H.A. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study // Br. Med. J. - 2000. - Vol. 321. - P. 412-419.

486.

487. Watkins P.J., Edmonds M.E. Diabetic autonomic failure // In:C.J. Mathias, R. Bannister, editors // Autonomic failure: a textbook of clinical disorders of the autonomic nervous system. - Oxford: University Press, 1999. - P. 378-386.

488.

489. Matthews D.R., Stratton I.M., Aldington S.J. et al. UK Prospective Diabetes Study Group. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69 // Arch. Ophthalmol. - 2004. - Vol. 122. - P. 1631-1640.

490.

491. Klein R., Klein B.E., Moss S.E. et al. The Wisconsin epidemiologic study of diabetic retinopathy. IX: four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years // Arch. Ophthalmol. - 1989. - Vol. 107. - P. 237-243.

492.

493. Gaede P., Vedel P., Larsen N. et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes // N. Engl.J. Med. - 2003. - Vol. 348. - P. 383-393.

494.

495. Beulens J.W., Patel A., Vingerling J.R. et al. on behalf of the AdRem_ project team and ADVANCE management committee. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial // Diabetologia. - 2009. - Vol. 52. - P. 2027-2036.

496.

497. Chaturvedi N., Porta M., Klein R. et al. DIRECT Programme Study Group. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials // Lancet. - 2008. - Vol. 372. - P. 1394-1402.

498.

499. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) // Lancet. - 1998. - Vol. 352. - P. 854-865.

500.

501. Mann J.F., Schmieder R.E., Dyal L. et al. TRANSCEND (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators. Effect of telmisartan on renal outcomes: a randomized trial // Ann. Intern. Med. - 2009. - Vol. 151. - P. 1-10.

502.

503. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease // Am. J. Kidney Dis. - 2004. - Vol. 43, № 5 (Suppl. 1). - P. S1-S290.

504.

505. Heerspink H.J., Ninomiya T., Zoungas S. et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomized controlled trials // Lancet. - 2009. - Vol. 373. - P. 1009-1015.

506.

507. PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result // Chin. Med. J. (Engl.). - 1995. - Vol. 108. - P. 710-717.

508.

509. Schrader J., Luders S., Kulschewski A. et al. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors // Stroke. - 2003. - Vol. 34. - P. 1699-1703.

510.

511. Potter J.F., Robinson T.G., Ford G.A. et al. Controlling hypertension and hypothension immediately post-stroke (CHHIPS): a randomized, placebo-controlled, double-blind pilot trial // Lancet Neurol. - 2009. - Vol. 8. - P. 48-56.

512.

513. Peters R., Beckett N., Forette F. et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial // Lancet Neurol. - 2008. - Vol. 7. - P. 683-689.

514.

515. Massie B.M., Carson P.E., McMurray J.J. et al. IPRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction // N. Engl. J. Med. - 2008. - Vol. 359. - P. 2456-2467.

516.

517. Vermes E., Tardif J.C., Bourassa M.G. et al. Enalapril decreases the incidence of atrial fi brillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials // Circulation. - 2003. - Vol. 17. - P. 2926-2931.

518.

519. Ducharme A., Swedberg K., Pfeffer M.A. et al. Prevention of atrial fi brillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program // Am. Heart J. - 2006. - Vol. 152. - P. 86-92.

520.

521. Wachtell K., Lehto M., Gerdts E. et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study // J. Am. Coll. Cardiol. - 2005. - Vol. 45. - P. 712-719.

522.

523. Schmieder R.E., Kjeldsen S.E., Julius S. et al. VALUE Trial Group. Reduced incidence of new-onset atrial fi brillation with angiotensin II receptor blockade: the VALUE trial // J. Hypertens. - 2008. - Vol. 26. - P. 403-411.

524.

525. Okin P.M., Wachtell K., Devereux R.B. et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fi brillation in patients with hypertension // J. Am. Med. Assoc. - 2006. - Vol. 296. - P. 1242-1248.

526.

527. Madrid A.H., Bueno M.G., Rebollo J.M. et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fi brillation: a prospective and randomized study // Circulation. - 2002. - Vol. 106. - P. 331-336.

528.

529. Fogari R., Mugellini A., Destro M. et al. Losartan and prevention of atrial fi brillation recurrence in hypertensive patients // J. Cardiovasc. Pharmacol. - 2006. - Vol. 47. - P. 46-50.

530.

531. Ueng K.C., Tsai T.P., Yu W.C. et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fi brillation. Results of a prospective and controlled study //Eur. Heart J. - 2003. - Vol. 24. - P. 2090-2098.

532.

533. Tveit A., Grundvold I., Olufsen M. et al. Candesartan in the prevention of relapsing atrial fi brillation // Int. J. Cardiol. - 2007. - Vol. 120. - P. 85-91.

534.

535. GISSI-AF Investigators. Valsartan for prevention of recurrent atrial fi brillation // N. Engl. J. Med. - 2009. - Vol. 360. - P. 1606-1617.

536.

537. Nasr I.A., Bouzamondo A., Hulot J.S. et al. Prevention of atrial fi brillation onset by beta-blocker treatment in heart failure: a meta-analysis //Eur. Heart J. - 2007. - Vol. 28. - P. 457-462.

538.

539. Turnbull F., Woodward M., Neal B. et al. Blood pressure lowering treatment Trialists' Collaboration. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials // Eur. Heart J. - 2008. - Vol. 29. - P. 2669-2680.

540.

541. Scranton R.E., Lawler E., Botteman M. et al. Effect of treating erectile dysfunction on management of systolic hypertension // Am.J. Cardiol. - 2007. - Vol. 100. - P. 552-553.

542.

543. Manolis A., Doumas M. et al. Sexual dysfunction: the 'prima ballerina' of hypertension-related quality-of-life complications //J. Hypertens. - 2008. - Vol. 26. - P. 2074-2084.

544.

545. Sever P.S., Dahlof B., Poulter N.R. et al. the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, Том 16, № 1 / 2010 in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial // Lancet. - 2003. - Vol. 361. - P. 1149-1158.

546.

547. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The antihypertensive and lipid-lowering treatment to prevent heart attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT) // J. Am. Med. Assoc. - 2002. - Vol. 288. - P. 2998-3007.

548.

549. Sever P., Dahlof B., Poulter N. et al. ASCOT Steering Committee Memberset. Potential synergy between lipid-lowering and blood-pressurelowering in the Anglo-Scandinavian Cardiac Outcomes Trial // Eur.Heart J. - 2006. - Vol. 27. - P. 2982-2988.

550.

551. Sever P.S., Poulter N.R., Dahlof B., Wedel H. on behalf of the ASCOT Investigators. Antihypertensive therapy and the benefi ts of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipidlowering arm extension // J. Hypertens. - 2009. - Vol. 27. - P. 947- 954.

552.

553. Ridker P.M., Danielson E., Fonseca F.A. et al. for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein // N. Engl. J. Med. - 2008. - Vol. 359. - P. 2195-2207.

554.

555. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials // Lancet. - 2009. - Vol. 373. - P. 1849-1860.

556.

557. Zanchetti A., Hansson L., Dahlof B. et al. Benefi t and harm of lowdose aspirin in well treated hypertensives at different baseline cardiovascular risk // J. Hypertens. - 2002. - Vol. 20. - P. 2301-2307.

558.

559. Zanchetti A. Aspirin and antiplatelet drugs in the prevention of cardiovascular complications in diabetes / In: C.E. Mogensen, editor // Pharmacotherapy of diabetes: new developments. - NY: Springer, 2007. - P. 211-218, chapter 19.

560.

561. Ogawa H., Nakayama M., Morimoto T. et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial // J. Am. Med. Assoc. - 2008. - Vol. 300. - P. 2134-2141.

562.

563. Jardine M.J., Ninomiya T., Cass A. et al. Aspirin benefit increases with declining renal function among people with hypertension //J. Hypertens. - 2009. - Vol. 27 (Suppl. 4). - P. S178. (abstract).

564.

565. Saudek C.D., Derr R.L., Kalyani R.R. Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c // J. Am. Med. Assoc. - 2006. - Vol. 295. - P. 1688-1697.

566.

567. ADVANCE Collaborative Group, Patel A., MacMahon S.,Chalmers J. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes // N. Engl. J. Med. - 2008. - Vol. 358. - P. 560-2572.

568.

569. Action to control cardiovascular risk in Diabetes Study Group,Gerstein H.C., Miller M.E., Byington R.P. et al. Effects of intensive glucose lowering in type 2 diabetes // N. Engl. J. Med. - 2008. - Vol. 358. - P. 2545-2559.

570.

571. Zoungas S., de Galan B.E., Ninomiya T. et al. on behalf of the ADVANCE Collaborative Group. The combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from ADVANCE // Diabetes Care. - 2009. [Epub ahead of print].

572.

573. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) // Lancet. - 1998. - Vol. 352. - P. 837-853.

574.

575. Duckworth W., Abraira C., Moritz T. et al. Glucose control and vascular complications in veterans with type 2 diabetes // N. Engl. J. Med. - 2009. - Vol. 360. - P. 129-139.

576.

577. Ray K.K., Seshasai S.R., Wijesuriya S. et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials // Lancet. - 2009. - Vol. 373. - P. 1765-1772.

578.

579. Indian Polycap Study (TIPS). Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial // Lancet. - 2009. - Vol. 373. - P. 1341-1351.

580.

581. Yusuf S. Two decades of progress in preventing cardiovascular disease // Lancet. - 2002. - Vol. 360. - P. 2-3.

582.

583. Wald N.J., Law M.R. A strategy to reduce cardiovascular disease by more than 80% // Br. Med. J. - 2003. - Vol. 326. - P. 1419.

584.


Для цитирования:


Статья Р. Обновление Европейских рекомендаций по лечению артериальной гипертензии: анализ Европейского Общества Гипертензии. Артериальная гипертензия. 2010;16(1):4-42.

For citation:


Article E. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2010;16(1):4-42. (In Russ.)

Просмотров: 122


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1607-419X (Print)
ISSN 2411-8524 (Online)